uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
9.75
-0.87 (-8.19%)
At close: Apr 3, 2025, 4:00 PM
9.74
-0.01 (-0.07%)
Pre-market: Apr 4, 2025, 9:18 AM EDT
uniQure Employees
uniQure had 209 employees as of December 31, 2024. The number of employees decreased by 271 or -56.46% compared to the previous year.
Employees
209
Change (1Y)
-271
Growth (1Y)
-56.46%
Revenue / Employee
$129,756
Profits / Employee
-$1,146,201
Market Cap
527.25M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
QURE News
- 5 weeks ago - uniQure Announces 2024 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 5 weeks ago - uniQure N.V.: A Potential Huntington's Play - Seeking Alpha
- 6 weeks ago - uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons - Seeking Alpha
- 7 weeks ago - uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years - Benzinga
- 7 weeks ago - CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B - PRNewsWire
- 2 months ago - uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease - GlobeNewsWire
- 2 months ago - uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS - GlobeNewsWire
- 3 months ago - uniQure Announces Pricing of its Public Offering - GlobeNewsWire